Eli Lilly Nears $1 Trillion Market Cap Driven by GLP-1 Blockbusters and Expanding Pipeline

In the pharmaceutical industry, surpassing a market value of 1 trillion U.S. dollars is a landmark achievement, representing the comprehensive strength of enterprises in R&D, market expansion, and financial performance. Eli Lilly and Company, with its strong R&D foundation and continuously expanding global market presence, has made remarkable progress toward this milestone. As Eli Lilly achieves significant breakthroughs with new drugs across multiple fields, investors and market analysts widely recognize its future growth potential.

As of now, companies such as Eli Lilly, Novo Nordisk, Johnson & Johnson, Merck, and AbbVie have joined the $100 billion market value club, with Eli Lilly ranking first.

The Competition of the Strong

In recent years, the GLP-1 receptor agonist market has become a focal point in the field of diabetes and obesity treatment. As a leader in this field, Novo Nordisk has maintained its dominant market position with its innovative products Ozempic and Wegovy.

However, global pharmaceutical giant Eli Lilly and Company is fiercely competing with its flagship GLP-1 drugs Zepbound and Mounjaro against Wegovy and Ozempic. This clash of titans not only reflects the competition between the two companies in technology and market strategy but also highlights the enormous potential of GLP-1 drugs in the global pharmaceutical market.

The increasingly intense competition between Novo Nordisk and Eli Lilly is also reflected in the second-quarter financial reports of these two pharmaceutical giants.

Eli Lilly ranked tenth among pharmaceutical giants with $11.3 billion in revenue for the second quarter of 2024. However, Ozempic secured the second place among blockbusters with $4.17 billion in Q2 revenue, just behind Merck's Keytruda, which generated $7.27 billion. Eli Lilly's Mounjaro ranked sixth with $3.09 billion.

Among the top 25 pharmaceutical giants by market value, Eli Lilly achieved a remarkable year-over-year sales growth rate of 36% in the second quarter of 2024, leading the pack. Moreover, since the second quarter of 2023, Eli Lilly's revenue has grown by at least 28% year-over-year each quarter. Novo Nordisk ranked second with a 27% year-over-year growth rate.

From the current situation, if we compare the sales of semaglutide-filled Wegovy and Ozempic with tirzepatide's corresponding Zepbound and Mounjaro, Eli Lilly's catch-up momentum appears very strong. In the first quarter of 2023 (when Zepbound had not yet received FDA approval), tirzepatide's sales were only 16% of semaglutide's, but by the second quarter of 2024, tirzepatide's sales had reached 74% of semaglutide's (Figure 1).

Figure 1. Quarterly sales trend comparison of Novo Nordisk's semaglutide products (Wegovy+Ozempic) and Eli Lilly's tirzepatide products (Zepbound+Moujaro). (Image source: Maven Bio)

By contrast, Novo Nordisk's semaglutide products Ozempic and Wegovy fell short of analysts' expectations in the second quarter due to supply issues. Novo Nordisk stated that quarterly sales of Wegovy grew by 53% to reach $1.7 billion, below the nearly $2 billion predicted by analysts.

As Eli Lilly and Novo Nordisk continue their博弈 in drug development, market promotion, and price competition, the battle for dominance in the GLP-1 drug market will become even more intense. Moreover, with the release of clinical trial results and the constant changes in market dynamics, the competitive momentum between Novo Nordisk and Eli Lilly will continue to escalate.

When will Eli Lilly join the "Trillion-Dollar Club"?

One of the most pressing questions is, when will Eli Lilly and Company join the "trillion-dollar club"?

What has helped Eli Lilly soar and approach the trillion-dollar market capitalization feat mainly comes from the momentum of Mounjaro and Zepbound. These two tirzepatide-based drugs, targeting type 2 diabetes and obesity respectively, have brought the company a continuous flow of wealth due to their tremendous success.

Mounjaro's sales in the second quarter of this year more than tripled to approximately $3.1 billion, surpassing the consensus expectation of $2.4 billion. The sales of the weight-loss drug Zepbound reached $1.2 billion, exceeding analysts' forecast of $819 million. Revenue from Mounjaro and Zepbound currently accounts for nearly 40% of Eli Lilly and Company’s total sales. Encouraged by the second-quarter sales performance, Eli Lilly raised its annual sales forecast by $3 billion, marking another upward revision after increasing the full-year sales forecast by $2 billion following the release of the first-quarter sales results.

Eli Lilly and Company's stock price has soared 65% this year, with its market value currently nearing $864.4 billion.

The most optimistic about Eli Lilly's stock direction are the analysts at Bank of America. After the latest earnings report was released, the Bank of America team raised their target price for Eli Lilly’s stock from $1,000 to $1,150. This is the highest price forecast on Wall Street, and if achieved, would push Eli Lilly's market value over $1 trillion. The Bank of America analysts also raised their revenue forecasts for Mounjaro/Zepbound in 2024, 2025, and 2026, citing "increased confidence in near-term supply dynamics."

Of course, risks lurk amidst the wave of optimism, with the main concern being the price of Eli Lilly's stock, which has a very high price-to-earnings ratio (the ratio of stock price to company earnings) of 60, compared to just 23 for the S&P 500 index. Even so, Eli Lilly's recent financial performance has indeed lived up to investors' high expectations.

Besides the tirzepatide product, Verzenio is another blockbuster product from Eli Lilly. In the first half of this year, the sales of this breast cancer drug soared by 42% year-over-year, reaching approximately $2.4 billion. Three other products in Eli Lilly's portfolio also continued to achieve double-digit percentage sales growth, such as the fast-acting insulin Humalog, the type 2 diabetes and chronic heart failure drug Jardiance, and the autoimmune disease drug Taltz.

In the Alzheimer's disease field, Eli Lilly also has the strength to dominate. Its Donanemab-azbt (Kisunla) received FDA approval on July 2 this year. The consensus on Wall Street is that the drug's peak annual sales will reach approximately $5 billion.

In Eli Lilly's pipeline, there are also the highly anticipated 3G weight-loss drugs (Glucagon/GLP-1/GIP triple receptor co-agonist) Retatrutide and the small molecule GLP-1 weight-loss drug Orfoglipron. Their pivotal Phase III data are expected to be released in 2026 and 2025, respectively.

In addition, there are four weight-loss assets in Phase I and II within Eli Lilly's pipeline.

In the long term, it seems only a matter of time before Eli Lilly's market value breaks through the trillion-dollar mark. This milestone not only signifies Eli Lilly's leading position in the pharmaceutical industry but will also further solidify its influence in the global capital market. For investors, although Eli Lilly's stock price is already relatively high, the company still holds significant growth potential due to its continuous innovation and market expansion.